{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 25,
  "pageCount": 40,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The slide uses a stacked bar chart to show revenue growth over time, segmented by region, alongside key performance indicators for US and Ex-US markets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/25",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.68,
        "y": 0.72
      },
      "kind": "callout",
      "text": "Accelerating uptake after reimbursement",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bda9470-1b2f-45cb-bdb9-05ccbdcf6877",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.35,
        "y": 0.72
      },
      "kind": "callout",
      "text": "New-patient share in BTK class now more than 40%",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee9bb407-c0f6-413d-b575-c2cf98494471",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Revenue growth by quarter and region",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f781acd7-567b-49aa-a1ab-35b1f408d881",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "list",
      "text": "US: high up-take in CLL: CLL c.3/4 of all Calquence use; >10% growth in CLL patient starts on BTKi; 1st line: >40% new-patient share; Large opportunity in reducing chemotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a0cfa21-63bd-4a29-a1ab-269f07fa4e83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "list",
      "text": "Ex-US: Europe launch and reimbursement underway: Approval 60 countries; Reimbursement 10 countries; Sales in >25 countries",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43075889-ea5f-4357-978a-d923d5280847",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.35,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1. Bruton's tyrosine kinase inhibitor. 2. Chronic lymphocytic leukaemia. Source: IQVIA market research. 3. Mantle cell lymphoma.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a439cadb-0744-4615-8e06-20e7bfa8f82a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Calquence: launch trajectory confirms clinical value Inflection point from chronic lymphocytic leukaemia uptake",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "773827de-3619-4756-9b88-8e2c4c4d05ef",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "9bb24be0-c8c7-49aa-a526-e9fcc4794b51",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps for investors.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cde01b8e-53ce-45e4-b3c4-d519c08ca374",
      "evidence": "The document implies that not investing in oncology would result in missed opportunities for growth and patient benefit.",
      "position": 1,
      "objective": "What are the consequences of not investing in oncology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}